GRC 8200

Glenmark Pharmaceuticals Europe Ltd. (R&D) · Phase 2 active Small molecule

At a glance

Generic name	GRC 8200
Sponsor	Glenmark Pharmaceuticals Europe Ltd. (R&D)
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRC 8200 CI brief — competitive landscape report
GRC 8200 updates RSS · CI watch RSS
Glenmark Pharmaceuticals Europe Ltd. (R&D) portfolio CI